Lupus & antiphospholipid syndrome
Identification of IFITM3 as a diagnostic biomarker of systemic lupus erythematosus and its association with disease activity based on multi-omics and experimental verification
Authors' conclusion
These findings indicated an obviously increased expression of IFITM3 in peripheral blood monocytes of patients with SLE and verified IFITM3 as a promising diagnostic marker for SLE and associated with disease activity.
Study context
- Population
- Patients with SLE and healthy controls; bulk RNA and scRNA-seq datasets from the Gene Expression Omnibus database
- Participants
- 68 vs 31
- Comparison
- SLE vs healthy controls
- SLEn = 68
- Healthy controlsn = 31reference
- Outcome
- Diagnostic value of IFITM3 for SLE and association with disease activity
Methodological detailsmulti-omics bioinformatic analysis, experimental verification
- Multi-omics bioinformatic analysis
- Experimental verification
Performance
As reported in the abstract
Diagnostic value of IFITM3 mRNA levels for SLE
| Test or model | AUC |
|---|---|
| SLE | 87.14% |
SLE
AUC87.14%
Further findings
Association with disease activity
- IFITM3 expression associated with SLEDAI, as well as C3, C4 and IgG levels
- IFITM3-positive group had a higher percentage of thrombocytopenia, leukopenia, low complement and fever (Chi-square test)
Original publication
Identification of IFITM3 as a diagnostic biomarker of systemic lupus erythematosus and its association with disease activity based on multi-omics and experimental verification. Lupus. Published 4 December 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →